- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: Yondelis.
Displaying page 1 of 1.
| EudraCT Number: 2009-011041-12 | Sponsor Protocol Number: ET-A-018-09 | Start Date*: 2009-07-23 | |||||||||||
| Sponsor Name:Pharma Mar S.A. | |||||||||||||
| Full Title: Étude multicentrique de phase Ib-II en escalade de dose de la trabectédine (Yondelis®) en association avec l’oxaliplatine chez des patientes atteintes d’un cancer de l’ovaire avancé prétraité. | |||||||||||||
| Medical condition: Pretreated Advanced Ovarian Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-000137-36 | Sponsor Protocol Number: TRAB1 | Start Date*: 2011-07-03 | |||||||||||
| Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO | |||||||||||||
| Full Title: USE OF TRABECTEDIN IN PATIENTS WITH RELAPSED/PROGRESSION OF EPITHELIAL CARCINOMA OVARY | |||||||||||||
| Medical condition: epithelial ovarian carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002186-56 | Sponsor Protocol Number: 2016/2410 | Start Date*: 2016-08-18 | ||||||||||||||||
| Sponsor Name:GUSTAVE ROUSSY | ||||||||||||||||||
| Full Title: Randomised phase III multicentric study comparing efficacy of doxorubicin with trabectedin followed by trabectedin in non-progressive patients versus doxorubicine alone as first-line therapy in pat... | ||||||||||||||||||
| Medical condition: Patients With Metastatic or Relapsed Unresectable Uterine or Soft Tissue Leiomyosarcoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: FR (Ongoing) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-022949-17 | Sponsor Protocol Number: ET-D-009-10 | Start Date*: 2010-10-20 | |||||||||||
| Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
| Full Title: Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of las... | |||||||||||||
| Medical condition: Advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) NL (Ongoing) DK (Completed) DE (Completed) ES (Completed) AT (Completed) NO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-001549-26 | Sponsor Protocol Number: TRASTS | Start Date*: 2014-11-03 |
| Sponsor Name:GEIS | ||
| Full Title: Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients. | ||
| Medical condition: Soft Tissue Sarcoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.